chrisvoncsefalvay/vaers-outcomes huggingface dataset:
given oral typhoid vax on 1APR94 began tablets that day; 7APR94 had fever, chills, body aches, h/a; sx lasted 3 1/2 days; completed series as directed w/last tablet on 7APR94;
Localized reaction with surrounding erythema & warmth at injection site (Right deltoid) x 2 weeks Symptoms: itching at site, redness & warmth, no pain
Pain/soreness to touch immediately after injection. The next morning there was significant redness and swelling (area approx. 3 inches across, injection site at the upper area of swelling) occasional burning sensation, pain with touch or movement of arm. ADVIL and icing helped but did not alleviate symptoms. 2nd day was the same. Beginning the 3rd day through the 7th day swelling and redness slowly diminished, but still painful to touch. The 8th day pain is gone, but still slightly discolored.
ANXIETY; This spontaneous report received from consumer concerned 64 patients. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose, start therapy date were not reported for prophylactic vaccination. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. No concomitant medications were reported. On an unspecified date, the subject experienced anxiety. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of anxiety was not reported. This report was non-serious.
Patient was waiting standard 15 minutes after her vaccination.  She said she felt dizzy, so she continued to wait.  At 6:45 pm (around an hour after her vaccine was given) she asked for a Benadryl.  She said her throat felt a little swollen.  She was given one 25mg diphenhydramine capsule.  She continued to wait at the pharmacy until 8pm when she said she felt better and then left.
Allergic reaction; Warm; Right arm being swollen; Itching; This spontaneous case was reported by a consumer and describes the occurrence of HYPERSENSITIVITY (Allergic reaction), VACCINATION SITE WARMTH (Warm), VACCINATION SITE SWELLING (Right arm being swollen) and VACCINATION SITE PRURITUS (Itching) in a 77-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025L20a) for COVID-19 vaccination.     The patient's past medical history included Radiation therapy (Left arm).    On 10-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 19-Jan-2021, the patient experienced HYPERSENSITIVITY (Allergic reaction), VACCINATION SITE WARMTH (Warm), VACCINATION SITE SWELLING (Right arm being swollen) and VACCINATION SITE PRURITUS (Itching). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) at a dose of 1 dosage form once a day. At the time of the report, HYPERSENSITIVITY (Allergic reaction), VACCINATION SITE WARMTH (Warm), VACCINATION SITE SWELLING (Right arm being swollen) and VACCINATION SITE PRURITUS (Itching) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were reported. She was advised to take an allergy pill.   Most recent FOLLOW-UP information incorporated above includes: On 15-Apr-2021: Follow up received and updated event outcome to recovered/resolved.
Patient started feeling metallic taste; Tingling on her tongue; Patient has a slight headache; This spontaneous case was reported by a patient and describes the occurrence of DYSGEUSIA (Patient started feeling metallic taste), PARAESTHESIA ORAL (Tingling on her tongue) and HEADACHE (Patient has a slight headache) in a 52-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 038A21A) for COVID-19 vaccination.     Concomitant products included TICAGRELOR (BRILINTA), VITAMIN D NOS and VITAMIN B COMPLEX for an unknown indication.    On 12-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .5 ml. On 12-Mar-2021, the patient experienced DYSGEUSIA (Patient started feeling metallic taste), PARAESTHESIA ORAL (Tingling on her tongue) and HEADACHE (Patient has a slight headache). At the time of the report, DYSGEUSIA (Patient started feeling metallic taste), PARAESTHESIA ORAL (Tingling on her tongue) and HEADACHE (Patient has a slight headache) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medications also included unspecified thyroid and pain medication.  Treatment information was not provided.
Started with dizziness then anaphylaxis like symptoms and lymph node symptoms of tingling lockjaw hard to swallow very difficult to breathe a little bit of chest pains, called EMS and paramedics to took blood oxygen levels, blood pressure which were all normal by then the symptoms had started to subside
pt recv vax;approx 10-11 hr p/ vax, intense screaming,lasted 24 hr w/ apap; refused to breast feed; terribly fussy 72 hr; appetite poor for 5 days;
Patient had immediate urticaria with a small rash that formed.  We gave the patient 25 mg of Diphenhydramine orally and the rash resolved and the urticaria improved
mom noticed 3/4" lump on lt leg this p/noon (1full wk p/vax); sl redness MD recommended warm packs, keep area clean-probable sterile abscess;
I woke up this morning to a huge red swollen area at and around injection site of my upper left arm. It measures 7 and three quarter inches long and 4 inches wide. It feels warm to touch and I have a tender armpit that has been a little swollen for a week. My left leg calf muscle has been achy and weird for a week also.
48 hours later, Pt threw up several times and diarrhea occurring same time as vomiting.
No additional adverse event details; a supported temperature excursion was administered to one patient; This spontaneous report as received from a physician refers to a patient of unknown age and gender. The patient's concurrent conditions, medical history, historical drug and concomitant therapies were not reported.  On an unspecified date, the patient was vaccinated with measles, mumps, rubella and varicella (oka-merck) virus vaccine live rHa (PROQUAD), 0.5 milliliter lot # T035393, expiration date 14-APR-2022 (route of administration and anatomical location not reported) for prophylaxis. Physician reported that with a supported temperature excursion was administered to one patient on 13-DEC-2021 (product storage error), temperature was 38F and time frame 16 hours and no previous temperature excursion. No additional adverse event details (no adverse event).
On 3/30/11, pt's parent called office with report of "huge, knot bump" following vaccine administration. CRNP assessed pt on 3/31. Pt found to have 6-7 cm red, warm, indurated nodule with tenderness. Pt given clindamycin 150 QID.
Office was notified of death of child by Epidemiologist of State on 06-05-2006. Sudden infant death on 05/31/2006 immunizations given on 05/25/2006. 7/31/06 Received autopsy report which stated COD as pneumonia with pathological diagnoses as bilateral acute hemorrhagic pneumonia; small reducible periunbilical hernia; slyphadenitis of mesenteric lymh nodes; & history of prematurity./ss
fatigue, headache, muscle aches, joint pain, chills, diarrhea, nausea, injection site pain, site tenderness, site swelling
bump in her arm; This spontaneous case was reported by a consumer and describes the occurrence of   in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No medical history reported.).    On 14-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) was unknown.       no concomitant medication provided no treatment taken
2nd dose Moderna COVID19 vaccine not received within timeframe; This spontaneous case was reported by a consumer and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (2nd dose Moderna COVID19 vaccine not received within timeframe) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 01-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 01-Mar-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (2nd dose Moderna COVID19 vaccine not received within timeframe). On 01-Mar-2021, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (2nd dose Moderna COVID19 vaccine not received within timeframe) had resolved. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medications was not provided by the reporter. Treatment information was not provided. Upon in internal review on 21 May 2021, the age was corrected to an unknown age.
Pain & stiffness: injection site within an hour of dose 3/12.  The next morning, (3/13) 9:30 am, I woke with severe pain all over my body. The worst pain was left arm, neck, back, buttocks, calves.  Moderate pain throughout the rest of my body, notably my torso and my jaw. I had terrible headaches throughout the day.  I was fatigued/exhausted and slept for several hours intermittently throughout the day. By 9PM I started to feel less fatigued, but the pain was very bad in most of my muscles. I felt like my muscles were battered and beaten, bruised and weak.  The next day (3/14) I started to have energy, but not a lot, around 11am, and  was still very sore, but the pain had subsided, and no more headaches. Today is 3/15, I am still very tired, but wouldn't call it fatigue, rather less energy than I am used to.  I have noticed that my back is still very sore, especially the intercostal muscles. My legs and buttocks are still very sore today.  I would not call it pain, but definitely notable and uncomfortable soreness.
numbness in fingertips, both hands,numbness in her hand, fingers tips, down the side of her hand; having trouble picking things up with her hands; This spontaneous case was reported by a consumer and describes the occurrence of HYPOAESTHESIA (numbness in fingertips, both hands,numbness in her hand, fingers tips, down the side of her hand) and GRIP STRENGTH DECREASED (having trouble picking things up with her hands) in a 62-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 032L20A and 036A21A) for COVID-19 vaccination.     No medical history were reported. .    On 14-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 04-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced HYPOAESTHESIA (numbness in fingertips, both hands,numbness in her hand, fingers tips, down the side of her hand) and GRIP STRENGTH DECREASED (having trouble picking things up with her hands). At the time of the report, HYPOAESTHESIA (numbness in fingertips, both hands,numbness in her hand, fingers tips, down the side of her hand) and GRIP STRENGTH DECREASED (having trouble picking things up with her hands) outcome was unknown.            No Concomitant medication was reported. No treatment medication was reported. No lab data has been provided by the reporter.
This case was reported by a consumer via call center representative and described the occurrence of pain in a 73-year-old female patient who received SHINGRIX for prophylaxis. Co-suspect products included SHINGRIX for prophylaxis. In May 2018, the patient received the 1st dose of SHINGRIX. On an unknown date, the patient received the 2nd dose of SHINGRIX. On an unknown date, 1 day after receiving SHINGRIX and not applicable after receiving SHINGRIX, the patient experienced pain and product supply issue. On an unknown date, the outcome of the pain was recovered/resolved and the outcome of the product supply issue was unknown. It was unknown if the reporter considered the pain to be related to SHINGRIX. Additional details were received as follows: The patient stated that she experienced achiness the next day after she received the 1st dose. The patient had not been able to get the 2nd dose within 6 months because of the lack of availability of the vaccine. The achiness lasted for 1 to 2 days before resolving. The reporter gave consent to follow up.
pt recvd vax;c/o rash to inner thighs; pt concerned about MMR vax given; MD stated poss rxn to MMR vax;
Pt received COVID vaccine on 3/31/21. Became COVID positive on 4/17/21. Admitted to the hospital on 4/17/21.
@ well pt exam age 1 on 6SEP91 mom related that pt became limp just p/recving immun; limpness reportedly lasted 20min; @ the time the shot were given on 15FEB91 pt was seen 10 min p/recvd injects by nurse who found pt sleeping & good color;
This report describes the occurrence of cellulitis in an 18 month old male who was vaccinated with diphtheria and tetanus toxoids and acellular pertussis vaccine absorbed (Infanrix) for prophylaxis. This report was received from the subject's mother and has not been verified by an MD or other healthcare prof'l. Reportedly, this subject had no relevant medical history, concurrent conditions, or concurrent medications. On 1/31/03, the subject reportedly received an injection of Infanrix (lot #DTPA573F9). The mother stated that one day later, on 2/1/03, the subject developed a "severe" reaction at the inject site characterized by swelling and redness that extended from the hip to the knee. The subject was seen by an MD who reportedly made a diagnosis of cellulitis. The subject was hospitalized and treated with 2 IM injection of vancomycin and oral amoxicillin clavulanate (Augmentin). The mother stated that by 2/2/03, the subject's log "was normal again." The subject was discharged from the hospital after an unspecified period of time. The mother considered the cellulitis to be probably related to Infanrix administration. The follow up received on 5/13/03 states the injection site cellulitis required intervention (IM ceftriaxone) in order to prevent hospitalization. Therefore, the event is considered to be serious (OMIC).
Varicella Vaccine breakthrough, diagnosed with atypical varicella on 10/02/06. Had 40-50 lesions. Coming out over 9 days.
Started to get sick / had symptoms; This is a spontaneous report received from a contactable reporter (Consumer or other non HCP) for a Pfizer sponsored program (159558). The reporter is the patient.  A male patient received bnt162b2 (BNT162B2), administration date 26Feb2021 (Batch/Lot number: unknown) as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: ILLNESS (non-serious) with onset 2021, outcome "recovered", described as "Started to get sick / had symptoms".  Additional Information: A week later after the first dose, he started to get sick. The patient's wife had COVID and the patient had symptoms but was already okay. The patient's second dose was supposed to be on 19Mar2021 and he wanted to know the protocol with missing his second dose.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
given an expired vaccine(expired 2/7/2023). I did called Jannsen and was notified that stability is still good 6 weeks after expiration date.
Pt has been having shortness of breath with dry cough for 4 days.  She lives with daughter and son who both have been diagnosed with COVID.
This spontaneous report was received from a medical assistant, concerning a patient of unknown age and gender. The patient's medical history, concurrent conditions, drug reactions or allergies were not provided. On 09-OCT-2018, there was an storage temperature excursion and on 08-NOV-2018, the patient was vaccinated with an improperly stored dose of M-M-R II lot # N035958 with expiration date on 18-DEC-2019 (strength, dose, anatomical location or route of administration were not provided), for prophylaxis; which was administered concomitantly with a sterile diluent (MERCK) that was not reported as improperly stored. The storage temperature of the vaccine was reported as 47 to 77 degrees Fahrenheit (°F) (58.5 °F) for a time frame of 13 hours and 20 minutes. There were no previous temperature excursions. Data logger was involved. No adverse effects were being reported. No product quality complaint (PQC) was involved. This is one of several reports received from the same reporter. Sender's Comments: US-009507513-1811USA012810.
Rash appeared at injection site after 4 days (10/2). It lasted for 3-4 days. It was treated with loratadine 10 mg once daily for 3-4 days.
3 d post vaccine hospitalized with orthostatic hypotension and vertigo 5 d post vaccine developed R face Bells Palsey
Difficult breathing due to tightened diaphragm Severe muscle aches Chills Headache Light-headedness
a lot of teachers were absent for quite a few days after vaccination; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of IMPAIRED WORK ABILITY (a lot of teachers were absent for quite a few days after vaccination) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced IMPAIRED WORK ABILITY (a lot of teachers were absent for quite a few days after vaccination). At the time of the report, IMPAIRED WORK ABILITY (a lot of teachers were absent for quite a few days after vaccination) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment information was not provided.  Concomitant medications was not reported by reporter.   This case was linked to MOD-2021-132767, MOD-2021-133049, MOD-2021-133172 (Patient Link).
5 Days of Flu like symptoms then sinus infection like feeling, contacted Doctor and put on anti-inflammatory pills, 1-2 months later still dealing with inflammation. Neurologist suggested NOT to receive 2nd shot due to inflammation, numbness and symptoms
Information has been received from a 28-year-old female who in 2001 and 2002 was vaccinated with a dose of varicella virus vaccine live (Oka/Merck). In approximately 2004 (2 years later) the patient had a negative titer. "A titer 5 years after the vaccination was positive." The patient sought medical attention via an office visit. A product quality complaint was not involved. Additional information has been requested.
ACUTE HYPOXEMIC RESPIRATORY FAILURE 8/6/2022 ANEMIA  HYPOXIA 9/6/2022 ANEMIA  ACUTE HYPOXEMIC RESPIRATORY FAILURE 8/6/2022 LUNG CANCER, LEFT LOWER LOBE  HYPOXIA 9/6/2022 LUNG CANCER, LEFT LOWER LOBE         ACUTE HYPOXEMIC RESPIRATORY FAILURE 8/6/2022 HTN (HYPERTENSION)  HYPOXIA 9/6/2022 HTN (HYPERTENSION)
Patient is a 79 y.o. female patient of a DO with PMH of CHF, Afib, HTN, DM presented to the ED due to weakness and falls.   Acute respiratory failure with hypoxia COVID-19 Date of onset of symptoms: 3/23 Symptoms present on admission: Fever, chils, Weakness.   Date of covid positive test: 3/24 Vaccination status: vaccinated & boosted Imaging: CXR with cardiomegaly and vascular congestion, cannot exclude atypical infection.  Oxygen requirements on admission: 2L NC Current oxygen requirements: room air Medical therapy: remdesivir and steroids. Doing well , can discontinue remdesivir after today  (Day 4/5)  and discharge home. To complete 10 days Decadron .  Consultants following: N/A Anticipated special isolation end date: 4/4/23   Generalized weakness Falls Likely secondary to COVID infection CT Head reviewed with no acute process but with mild old microvascular ischemic changes and age related volume loss, small old infarct in right parietal lobe.  CT C spine with no acute process PT/OT consulted.  Doing much better. Ambulatory without difficulty.    DM type II with hyperglycemia Diabetic neuropathy HBA1C 8.6. Holding home medications Lantus and SSI started.  Adjust as needed as patient on steroids Resume gabapentin. Hyperglycemia due to steroids. Resume home meds at dicharge.    Paroxysmal Atrial fibrillation Chronic diastolic heart failure Euvolemic on exam. EKG personally reviewed showing NSR BNP 1077 Troponin 17 -- > 18 Resume home lasix, metoprolol, Xarelto. Monitor on tele   Essential HTN Resume losartan.
Vaccines administered 12/29/05.  On 1/7/06 patient had a 30 sec episode where eyes were deviated to right side and was seen at ER (was febrile) and thought to have a febrile seizure.  Patient was referred to Neurology.
RIGHT SIDED FACIAL NUMBNESS AND TINGLING (BELL'S PALSY) 62 DAYS FOLLOWING ADMIN OF FLUMIST
Soreness in arm; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Soreness in arm) in a 56-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 029L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 11-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PAIN IN EXTREMITY (Soreness in arm). At the time of the report, PAIN IN EXTREMITY (Soreness in arm) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant and treatment medication were provided   This case was linked to MOD-2021-045602 (Patient Link).
almost immediately after all vaccines were given to patient he develop urticaria/red erythematous patches like lesions only in bilateral Lower extremities.  No other lesions were noted above trunk region.  No respiratory issues.  No swelling.  Patient was given benadryl in office and rash began to subside after monitoring patient for 15 min in the office.
patient had dizziness and felt hot and very pale,. took her blood pressure, applied ice packs, had her lay down. She felt better in about 30minutes
tired; headache; joint pain; couldnt lift my arm; This is a spontaneous report received from a contactable consumer (patient). This 63-year-old male patient received dose 1 of bnt162b2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE; lot number El9267) on 20Feb2021 at 11:00 as a single dose in the left arm for COVID-19 immunization. Medical history was none. The patient did not receive any other vaccines within 4 weeks prior to the vaccine. The patient was not diagnosed with COVID-19 prior to the vaccine. Concomitant medications included atorvastatin, metoprolol, and losartan from unknown dates for unknown indications. The patient previously received warfarin (COUMADIN) from an unknown date and experienced allergy. On an unspecified date the patient experienced joint pain severe for 14 days, tired for 14 days, headache for 14 days, and couldn't lift his arm for 3 days. The events were reported as non-serious. The patient was not hospitalized for the events. The outcomes of joint pain severe, tired, headache, and couldn't lift arm were unknown. It was also reported that since the vaccination the patient had not been tested for COVID-19.   No follow-up attempts are needed. No further information is expected.; Sender's Comments: Linked Report(s) : PFIZER INC-2021400134 Same patient and drug, different dose/events
8 pm 12/8/09 Headache, chills, temperature max of 101.9. Left arm with increased redness, swelling, and pain with lymph node soreness. Diarrhea 12/9/09 with body aches.